CommercialPrior AuthMedium impact
08.00.66x, Bevacizumab (Avastin®) and Related Biosimilars For Oncologic Use
Independence Blue Cross·Oncology·Pharmacy
Effective date
Mar 23, 2026
We identified it
Jun 19, 2026
Summary
The bevacizumab (Avastin®) and biosimilars policy for oncologic use has been updated with changes to medical necessity criteria and medical coding requirements. This affects billing and coverage determination for cancer treatment medications administered in oncology practices.
Action Required
Before March 23, 2026: Billing team must review updated medical necessity criteria for bevacizumab (Avastin®) and related biosimilars used in cancer treatment. Update prior authorization processes and documentation requirements per the revised policy. Ensure oncology providers are aware of new coding requirements to prevent claim denials.